NCT07214870

A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NNC4005-0001 in Adults

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.

Conditions

• Fatty Liver Disease

Interventions

Type	Name	Description
DRUG	NNC4005-001	NNC4005-0001 will be given as a single ascending dose via subcutaneous route
DRUG	Placebo	Placebo matched to NNC4005-0001 will be given via subcutaneous route

Timeline

• Start date: 2025-10-08
• Primary completion: 2027-05-14
• Completion: 2027-05-14
• First posted: 2025-10-09
• Last updated: 2026-02-11

Locations

1 site across 1 country: Canada